SoonerTrack Update: Due to the ongoing PeopleSoft implementation, SoonerTrack will tentatively be down from
noon on Saturday the 27th to noon on Sunday the 28th. This time is subject to change and we will keep you posted.
A Walk-Through of the PHS Human Subjects and Clinical Trials Information Form
PHS has updated their video to align with the latest form update (FORMS-F).
OMB M-20-26: Extension of Administrative Relief for Recipients and Applicants of Federal Financial
Assistance (COVID-19) - a memo was published by OMB, extending certain of the flexibilities provided by M-20-17.
NIH WILL ACCEPT PRELIMINARY DATA AS POST-SUBMISSION MATERIAL AND OTHER COVID-19 RELATED
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI
Website ( http://octsi.ouhsc.edu/covid-19%20working%20group ) A list of investigators in the working group and their
planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is
also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please
contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and
Immunology, OUHSC ( email@example.com ).
Oklahoma Shared Clinical and Translational Resources Clinical and Translational Research Pilot
The purpose of the program is to provide funding for collaborative and/or multi-disciplinary clinical and translational
pilot projects between investigators of the OSCTR member institutions. The program seeks to support proposals
designed to generate preliminary data that will result in improved health and/or healthcare for citizens of Oklahoma
and other IDeA states and enhance the competitiveness of the investigators for future extramural funding. The
program also seeks to fund innovative concepts, approaches, and methodologies that bring fresh new ideas to
solving the health issues of those living in Oklahoma and collaborating IDeA states. Projects that focus on the
medically underserved and on health concerns prevalent within Oklahoma and our OSCTR partners will be a priority.
Only projects which meet the NIH definition of clinical and/or translational research will be accepted.
Approved CTRP grants will be funded for a period starting January 1, 2021 contingent on NIH approval of just in
time (JIT) information. All funds are required to be expended by December 31, 2021.
The forms, instructions, and submission link can be found at: http://osctr.ouhsc.edu/pilots2020
Deadlines for submission: Pilot Proposal – Friday, August 7, 2020 at 5:00 PM CDT
Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory
This program is intended to support community engagement to develop funded research partnerships. Funds can be
used for research development activities, including convening partners, working with individuals pursuing related work,
and conducting needs assessments in community settings. The funds cannot be used to support actual human-subjects
research protocols, which can be funded under other OSCTR pilot research programs and/or external funding.
The application should consist of a 2-page letter from the main applicant (which can be either a community agency or
an academic researcher) describing the collaboration, the contributions that the proposed work will make to a successful
research partnership, and a line item budget. Budget requests are expected to be $5,000-$10,000 with budgets that
permit the expenditure of the entire award by June 30, 2021. A separate letter of support from either the academic or
community partner indicating their agreement with the proposed activities should also be included. Proposals will be
evaluated on a rolling basis beginning July 1, 2020. Please submit proposals by email to firstname.lastname@example.org.
Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting
the OSCTR staff at email@example.com or call 405-271-3480.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/OSCTR Pilot instructions 2020.pdf?ver=2020-06-15-070451-763
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/OSCTR CERE instructions 2020.pdf?ver=2020-06-15-070451-780
Office of Technology Commercialization presents a new opportunity to engage with industry (email firstname.lastname@example.org
or email@example.com for specific submission details):
Astellas Pharma is looking to engage with academia for developing novel early-stage small molecule compounds
having potential to cure disease (OUT OF SCOPE: cancer, infectious disease, metabolic disease, CNS disease, rare
diseases). Non-confidential summary application (~template available~) due July 20th, 2020.
- Significant in vivo efficacy that can reverse pathophysiology
- Drug-like properties
- Higher activity in target cell
- Higher target specificity
- Clarified direct target binding and/or modification
For additional information, go to: http://www.ou.edu/otc/ICO
The OU Medicine Laboratory is looking for equipment to assist with their COVID-19 testing. Please see the
attached list of equipment needs. Please reply to VPR@ouhsc.edu if you have any of this equipment you could possibly loan.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/COVID Ramp Up Ask List.docx?ver=2020-06-01-083246-413
DONATION OF TESTING SUPPLIES
OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the Testing
supplies listed in the attached “Testing Donations”. Please return the complete form to Kristen.Namey@oumedicine.com.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Testing Donations.xlsx?ver=2020-06-01-083249-427
DONATION OF PPE SUPPLIES
OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the PPE
supplies listed in the attached “research PPE donation”. The first line is an example of how to fill out the form. Please
return completed form to Erin-Bailey@ouhsc.edu.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Copy of research PPE donation.xlsx?ver=2020-06-01-083245-163
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
Fast-Grants – Fast Funding for COVID-19 Science
NIH has created a central site for its current COVID-19 guidance at
OUHSC Financial Administrators:
The federal and state governments are asking that all institutions track their expenditures related to the
COVID-19 pandemic. It is imperative that everyone is diligent in tracking all COVID-19 related expenditures for future
reimbursement opportunities. Effective immediately, all COVID-19-related expenditures incurred since March 12 should be
coded to a newly created COVID subclass. These expenditures include, but are not limited to direct COVID-19 costs,
increased housekeeping and maintenance costs, expenditures related to business process modifications, preparatory actions,
daily operations, and communications resulting from COVID-19. If COVID related expenses, since March 12, have already
been paid, please process a cost transfer using the new COVID subclass. Research faculty and staff should also track their
expenditures incurred by the shutdown of their projects and laboratories including the loss of samples, reagents, animals
and other items. Also, keep in mind that, asyou resume your activities in your lab, any expenses required to restart the lab
should be coded with the COVID subclass. This will help significantly when applying for any administrative supplements or
other COVID-19 related relief efforts. Questions regarding the use of the subclass on non-research chartfields should be
forwarded to firstname.lastname@example.org and research related questions can be sent to email@example.com.
OUHSC Funding Requests related to COVID-19 – when submitting an item in the OUHSC SoonerTrack system
related to COVID-19 please include “COVID-19” in the title so that we are able to search on it later.
COVID-19/Coronavirus Resources – a list from InfoEd
Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research
on Coronavirus Disease 2019 (COV-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Attention: OUHSC FY20 State Contract Budget Planning
F&A (IDC) are real costs incurred by the department and the University in support of sponsored activities. The funding
derived from F&A provides critical dollars necessary to support the operating expenses related to the space in which the
project is conducted, as well as the various services provided to the Principal Investigator and the college and department
for administering the contract (e.g., accounting, purchasing, human resources). Without appropriate recovery of F&A costs,
the University loses money and we must be fiscally responsible to our tax payers and students. It is not responsible
stewardship to waive these costs. Since this is the time of year when a lot of departments and faculty start their FY21 budget
planning for their anticipated state contracts, we wanted to remind everyone that no F&A reduction or waiver requests will be
approved this year. As always, Please see this link for current F&A rates:
To review OUHSC Facilities and Administration Policy for Externally Funded Projects, please see this link:
Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic (NOT-OD-20-123)
Pre-Application Webinar for NCI's Serological Sciences Network Funding Opportunities (RFA-CA-20-038, RFA-CA-20-039)
Notice of Clarification to PAR-19-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)"
Notice of Pre-Application Webinar and Frequently Asked Questions (FAQs) for PAR-20-220 " Institutional Network Award for
Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1 - Clinical Trial Not Allowed) " (NOT-DK-20-027)
Notice of Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences
Notice of Availability of National Children’s Study (NCS) Vanguard Biological and Environmental Sample Materials
Notice of Participation of National Institute of Nursing Research (NINR) in PA-20-135 "Emergency Competitive Revision
to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional")
Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision
Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency
Guidance Regarding Change in Status, Including Absence of PD/PI and Other Key Personnel Named in the Notice of Award
Notice of Pre-Application Webinars for the High-Risk, High-Reward Research Program's Pioneer, New Innovator, Transformative
Research, and Early Independence Awards (NOT-RM-20-021)
Request for Information: Soliciting Input on the NIGMS 2021-2025 Strategic Plan Framework
Notice of NLM's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement –
Clinical Trial Optional)" (NOT-LM-20-012)
Notice of NIMH Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement –
Clinical Trial Optional)" (NOT-MH-20-064)
Notice of Extension of the Response Date for NOT-NS-20-026 "Request for Information: Soliciting Input on Areas of Health
Disparities and Inequities in Neurological Disease and/or Care in the United States Across the Lifespan" (NOT-NS-20-075)
Notice of Change in Application Due Date for NOT-OD-20-107 "Notice of Special Interest (NOSI): Administrative Supplements
to Existing NIH ECHO Cooperative Agreements (Admin Supp - Clinical Trial Not Allowed) for COVID-19 related Research"
Notice of Intent to Publish a Funding Opportunity Announcement for INIA Research Project (U01 Clinical Trial Optional)
Notice of Special Interest (NOSI): NIAID Priorities for Biomedical Knowledgebases and Repositories
Notice of Special Interest (NOSI): Role of Astrocytes and Astrocytic Networks in Drug Abuse
Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases
Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications
(SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19
Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-120)
Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged
Research on COVID-19 Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-121)
Please Note: When only one application is allowed per Institution according to the sponsor
instructions, a one-page letter of intent summarizing the proposed project should be submitted
to the Vice President for Research at least two months prior to the application deadline (unless
otherwise noted). The letters of intent will be reviewed and a single application will be chosen
for submission from the University.
Administrative Supplement for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed) (PA-20-227)
Deadline October 15, 2020 and January 15, 2021
Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanicals and Other Natural Products
(PI2 CARBON) (R03 Clinical Trials Not Allowed) (PAR-20-228) - Deadline October 1, 2020 and June 1, 2021
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) (PAR-20-229)
Deadline August 14, 2020 and August 3, 2021
Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01)
(PAR-20-230) – Deadline Continuous
Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)
(RFA-AG-21-024) - Deadline October 29, 2020
Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional)
(RFA-CA-20-035) – Deadline September 4, 2020
Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional)
(RFA-CA-20-036) – Deadline September 4, 2020
Collaborative Centers in Children's Environmental Health Research and Translation Centers (P2C Clinical Trial Optional)
(RFA-ES-20-001) - Deadline November 23, 2020
Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)
(RFA-OD-20-013 - Deadline August 7, 2020